

Cushing's disease: experience in a third level hospital from Zaragoza (Spain)

Authors: F. Losfablos MD, P. de Castro Hernández MD, P. W. Trincado Aznar MD, M. Monreal Villanueva MD, J. Acha Pérez MD

Hospital: Servicio de Endocrinología y Nutrición. Hospital Universitario Miguel Servet. Zaragoza. Spain

Topic: Adrenal

Objectives

- Cushing's disease (CD) is caused by pituitary corticotrophin (ACTH)-secreting tumors.
- Our aim is to show our experience in a third level hospital attending a 500000 based population area from 1990 to now.
- We want to compare our experience with data collected from other series
- We want to know the patient profile we are attending to elucidate the best way to manage them

Methods

- we review retrospectively the medical reports of all patients diagnosed as CD from 1990 by a data collection protocol.
- We design an algorithm protocol to review in the same order the medical information of our patients
- We reject the reports we consider have not enough information or have inadequate information.
- We present results by using descriptive statistics

Results

29 patients were diagnosed as CD in the period study (estimate average incidence of 2,41 cases per million people per year). 9 medical reports contain insufficient or misleading information including 2 from dead patients. The remaining 20 patients were included in our analysis. Main results are presented in tables 1-4 and in figure 1.

Table 1. Population characteristics

Age at diagnosis	39 years (17-75)
Women	90%
Body mass index	28,45 kg/m ² (19,55-44,6)
Follow up time	11 years (2-24)


Table 2. Clinical characteristics

Most common reference reason	55% hyperandrogenism 25% facial/troncal adiposity
Most common symptom	65% hirsutism 55% obesity/weight gain 55% HTA/DM worsening 55% muscle weakness, fatigue 50% ecchymosis

Table 3. Diagnostic findings

cortisol rhythm	with	12,5%
	without	87,5%
	inverted	31,25%
plasma basal cortisol		27,9 mcg/dl (18-51)
plasma basal ACTH		71,96 pg/ml (20-231)
plasma cortisol after 1 mg DXM (test A)		14,6 mcg/dl (3,38-34,9)
plasma cortisol after 4 mg DXM		14,53 mcg/dl(3,08-23,46)
plasma cortisol after 8 mg DXM (test B)		7,96 mcg/dl(0,34-24,45)
difference between test A and test B		-5,6 mcg/dl(-17,7- +2)
plasma cortisol at midnight		13,63 mcg/dl (9,26-18,03)
24-h free urinary cortisol		840,7 mcg/24-h(97-5530)
MRI	any finding	35%
	microadenoma	55% (2 mm to 10 mm)
	macroadenoma	10% (12 mm and 45 mm)
inferior petrosal sinus sampling		done before treatment
	70%	
	undone	20%
	done after first line treatment	5%
	done after second line treatment	5%
peak ACTH value		2560,45 pg/ml(182-11100)
	right lateralization	45%
	left lateralization	35%
	no lateralization	20%
pituitary hispopathology	no findings	20%
	multisecretor tumor	60%
	only ACTH-secreting tumor	20%

figure 1. Treatment



conclusions

- our patients reproduce well referenced data from other series epidemiologically, clinically and in their global outcomes. We have a ratio slightly worse for surgical cure than other recent series.
- hyperandrogenism was the main cause of consultation and the most common symptom
- 12,5% of patients keep their diurnal physiological variation of cortisol secretion
- the suppression test with 4 mg of DXM contributed nothing to the diagnosis apart from the 1 mg DXM suppression test
- the minimum threshold cortisol value in the 1 mg DXM suppression test of our patients was 3,38 mcg/dl and the minimum midnight plasma cortisol value was 9,26 mcg/dl.
- plasma cortisol in the 8 mg DXM suppression test was highly variable and less helpful in our serie.
- 24-h free urinary cortisol threshold value of 200 mcg/24-h have a diagnostic sensitivity of 92% in our serie.
- 70% of patients have required inferior petrosal sinus sampling to confirm the pituitary ACTH-hypersecretion before entering the surgical procedure.
- worsening of vascular risk factors and loss of bone mass were the main complications of CD before and during diagnostic procedure.
- pituitary deficiencies and perisurgical diabetes insipidus and nasal liquorrhea are the main complications after treatment.
- It would be desirable to develop uniform diagnostic protocols through different hospitals and countries

Table 4. Complications

osteoporosis		30%
osteopenia		45%
hypopituitarism	presurgery	5%
	postsurgery	15%
nasal liquorrhea		20%
diabetes insipidus		10%
need for cronic hydrocortisone supplementation		35%
meningitis		5%
derivation to intensive care unit		5%
death		0% (2/29,6,8%)

bibliography

1. Wind JJ, Lonser RR, Nieman Lk et al. The lateralization accuracy of inferior petrosal sinus sampling in 501 patients with Cushing's disease. J Clin Endocrinol Metab. 2013 Jun;98(6):2285-93
2. Tomycz ND, Horowitz MB. Inferior petrosal sinus sampling in the diagnosis of sellar neuropathology. Neurosurg Clin N Am. 2009 Jul;20(3): 361-7.
3. Huguet I, Aguirre M, Vicente A et al. Assessment of the outcomes of the treatment of Cushing's disease in the hospitals of Castilla-La Mancha. Endocrinol Nutr. 2015 Apr 15;1575-0922(15)00077-7.
4. Lewis S, Blevins Jr, Nader Sanai, Sandeep Kunwar et al. An approach to the management of patients with residual Cushing's disease. J Neurooncol. 2009 Sept;94(3):313-19.
5. Roelfsema F, Biermasz NR, Pereira AM. Clinical factors involved in the recurrence of pituitary adenomas after surgical remission: a structured review and meta-analysis. Pituitary. 2012 March;15(1):71-83.
6. Geer EB. Characterization of persistent and recurrent Cushing's disease. Pituitary. 2014;17(4):381-389
7. Lambert JK, Goldberg L, Fayngold S et al. Predictors of mortality and long-term outcomes in treated Cushing's disease: a study of 346 patients. J Clin Endocrinol Metab. 2013 Mar;98(3):1022-1030.

